

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6185)

POLL RESULTS OF THE 2019 FIRST EXTRAORDINARY GENERAL MEETING, THE 2019 FIRST CLASS MEETING OF H SHAREHOLDERS AND THE 2019 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS AND UNLISTED FOREIGN SHAREHOLDERS

CHANGE OF MEMBERS OF THE BOARD OF DIRECTORS AND ITS COMMITTEES

AND

CHANGE OF MEMBERS OF THE BOARD OF SUPERVISORS

POLL RESULTS OF THE EGM AND CLASS MEETINGS

The Board hereby announces that the poll results in respect of the resolutions proposed at the EGM and the Class Meetings held on Friday, November 29, 2019. All resolutions were duly passed.

CHANGE OF MEMBERS OF THE BOARD OF DIRECTORS AND ITS COMMITTEES

The Board hereby announces that (i) Mr. Shuifa GUI has been appointed as an independent non-executive Director of the Company and elected as the chairman of the Remuneration and Assessment Committee and a member of the Nomination Committee; and (ii) Mr. Jianzhong LIU has been appointed as an independent non-executive Director of the Company and elected as a member of the Remuneration and Assessment Committee and the chairman of the Nomination Committee.

Dr. Pierre Armand MORGON ceased to be an independent non-executive Director of the Company, the chairman of the Remuneration and Assessment Committee and a member of the Nomination Committee upon conclusion of the EGM. Dr. Luis BARRETO ceased to be an independent non-executive Directors of the Company, a member of the Remuneration and Assessment Committee and a member of the Nomination Committee upon conclusion of the EGM. Dr. Xuefeng YU ceased to be the chairman of the Nomination Committee and continues to be a member of the Nomination Committee upon conclusion of the meeting of the Board held on November 29, 2019.

CHANGE OF MEMBERS OF THE BOARD OF SUPERVISORS

The Board hereby announces that Ms. Jiangfeng LI has been appointed as a supervisor and the chairman of the board of supervisors of the Company.

Mr. Jixiang ZHU ceased to be a supervisor and the chairman of the board of supervisors of the Company upon conclusion of the EGM.

CanSino Biologics Inc. (the “**Company**”) announces that at its 2019 first extraordinary general meeting (the “**EGM**”), the 2019 first class meeting of H shareholders (the “**Class Meeting of H Shareholders**”) and the 2019 first class meeting of domestic shareholders and unlisted foreign shareholders (the “**Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders**”, together with the Class Meeting of H Shareholders, the “**Class Meetings**”) held on November 29, 2019, all resolutions proposed were duly passed. The EGM and Class Meetings were convened by the Board.

Further details of the resolutions are set out in the notice of the EGM dated October 14, 2019 (as supplemented by the supplemental notice dated November 14, 2019), the notice of Class Meeting of H Shareholders dated October 14, 2019, the notice of Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders dated October 14, 2019, the circular dated October 14, 2019 (the “**Circular**”) and the supplemental circular dated November 14, 2019 (the “**Supplemental Circular**”).

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular and the Supplemental Circular.

ATTENDANCE AT THE EGM AND CLASS MEETINGS

The Board is pleased to announce that the EGM and Class Meetings were held at Conference Room, Level 11, CITIC Securities Tower, No. 48 Liangmaqiao Road, Chaoyang District, Beijing on November 29, 2019.

The attendance of the EGM and Class Meetings is as follows:

	Class of Shares	Number of Shares in issue (and entitling holders to attend and vote for or against any resolution)	Number of Shares present (in person or by proxy)	Approximate %
EGM	H Shares	132,670,900	108,918,526	82.10%
	Domestic Shares and Unlisted Foreign Shares	89,978,999	89,978,999	100.00%
	Total	222,649,899	198,897,525	89.33%
Class Meeting of H Shareholders	H Shares	132,670,900	109,168,526	82.29%
Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders	Domestic Shares and Unlisted Foreign Shares	89,978,999	89,978,999	100.00%

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the EGM and Class Meetings as set out in rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM and Class Meetings; and (3) no party has stated any intention in the Circular and the Supplemental Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM and Class Meetings.

POLL RESULTS OF THE EGM

The poll results of the EGM were as follows:

	Special Resolutions⁽¹⁾	For	Against	Abstain	Passed by Shareholders⁽²⁾
1.	To consider and approve the fulfillment by the Company of the requirements for initial public offering of A Shares and listing on the SSE STAR Market.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
2.	To consider and approve the proposed Issue of A Shares as follows:	(each and every item as a separate resolution)			
	(i) Class of new Shares to be issued;	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(ii) Nominal value of new Shares to be issued;	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(iii) Issue size;	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(iv) Method and schedule of issuance;	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(v) Target subscribers;	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(vi) Pricing methodology;	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(vii) Issuance expenses;	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(viii) Method of underwriting;	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(ix) Subscription by the Company's senior management and core employees;	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(x) Place of listing;	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(xi) Validity period of the resolutions.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes

Special Resolutions⁽¹⁾		For	Against	Abstain	Passed by Shareholders⁽²⁾
3.	To consider and approve the investment projects to be funded by the proceeds raised from the Issue of A Shares and feasibility analysis.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
4.	To consider and approve the authorization to the Board of Directors to fully handle matters in connection with the proposed Issue of A Shares and the listing on the SSE STAR Market.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
5.	To consider and approve the proposal for accumulated profit distribution and the plan for undertaking unrecovered losses prior to the Issue of A Shares.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
6.	To consider and approve the Company's three-year dividend distribution plan for Shareholders after Issue of A Shares and listing on the SSE STAR Market.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
7.	To consider and approve the Company's share price stabilization plan and restraining measures within three years after the Issue of A Shares and listing on the SSE STAR Market.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
8.	To consider and approve the undertakings and restraining measures relating to the Issue of A Shares and listing on the SSE STAR Market, and to authorize the Board to make appropriate undertakings for the purpose of the Issue of A Shares in accordance with the laws, regulations and regulatory documents of the PRC, the relevant regulations and policies of the securities regulatory departments, and combining the review for listing on the SSE STAR Market in practice and the actual situation of the Company.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
9.	To consider and approve the impact of dilution on immediate return by the Issue of A Shares and adoption of recovery measures.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
10.	To consider and approve the proposed amendments to the Articles in respect of the Issue of A share.	175,908,925 (88.44%)	22,988,600 (11.56%)	0 (0.00%)	Yes

Special Resolutions⁽¹⁾		For	Against	Abstain	Passed by Shareholders⁽²⁾
11	To consider and approve the proposed amendments to the Articles concerning the notice period of the general meeting, shareholders' proposal right and convening procedures, and authorize the Board to amend relevant internal policies accordingly.	175,307,199 (88.14%)	23,590,326 (11.86%)	0 (0.00%)	Yes
Ordinary Resolutions⁽¹⁾		For	Against	Abstain	Passed by Shareholders
12.	To consider and approve the proposed amendments to the Company's internal management policies, namely, the "Rules of Procedures for the Meeting of Shareholders", the "Rules of Procedures for the Board of Directors", the "Rules of Procedures for the Board of Supervisors", "Management Policies for Raised Funds", "Management Policies for Related Transactions", the "Administrative Policies for External Guarantees", the "Administrative Policies for External Investment", the "Terms of Reference for the Independent Non-Executive Directors".	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
13.	To consider and approve the engagement of professional intermediaries, including the sponsor/lead underwriter, legal adviser and auditor for the Proposed Issue of A Shares and listing, and to authorize the Board of Directors to determine the relevant remuneration of the aforementioned intermediaries, including but not limited to CITIC Securities Co., Ltd., China International Capital Corporation Limited, Tian Yuan Law Firm and PricewaterhouseCoopers Zhong Tian LLP.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
14.	To consider and approve the uncovered deficit of the Company amounting to one-third of the total share capital.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
15.	To consider and approve the report on the use of proceeds raised in previous offering by the Company.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes

Ordinary Resolutions ⁽¹⁾		For	Against	Abstain	Passed by Shareholders
16.	To consider and approve the proposed appointment of Mr. Shuifa GUI as independent non-executive director of the Company.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
17.	To consider and approve the proposed appointment of Mr. Jianzhong LIU as independent non-executive director of the Company.	198,897,525 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
18.	To consider and approve the proposed appointment of Ms. Jiangfeng LI as supervisor of the Company.	189,882,325 (95.47%)	9,015,200 (4.53%)	0 (0.00%)	Yes

Notes:

- (1) Please refer to the notice of the EGM, the Circular and the Supplemental Circular for details of these resolutions.
- (2) An ordinary resolution is passed by more than half of votes casted in favour of it, and a special resolution is passed by more than two-thirds of the votes casted in favour of it.

POLL RESULTS OF THE CLASS MEETING FOR H SHAREHOLDERS

The poll results of the Class Meeting for H Shareholders were as follows:

	Special Resolutions ⁽¹⁾	For	Against	Abstain	Passed by Shareholders ⁽²⁾
1.	To consider and approve the fulfillment by the Company of the requirements for initial public offering of A Shares and listing on the SSE STAR Market.	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
2.	To consider and approve the proposed Issue of A Shares as follows:	(each and every item as a separate resolution)			
	(i) Class of new Shares to be issued;	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
	(ii) Nominal value of new Shares to be issued;	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
	(iii) Issue size;	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
	(iv) Method and schedule of issuance;	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
	(v) Target subscribers;	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
	(vi) Pricing methodology;	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
	(vii) Issuance expenses;	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
	(viii) Method of underwriting;	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
	(ix) Subscription by the Company's senior management and core employees;	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
	(x) Place of listing;	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
	(xi) Validity period of the resolutions.	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
3.	To consider and approve the investment projects to be funded by the proceeds raised from the Issue of A Shares and feasibility analysis.	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes

Special Resolutions⁽¹⁾		For	Against	Abstain	Passed by Shareholders⁽²⁾
4.	To consider and approve the authorization to the Board of Directors to fully handle matters in connection with the proposed Issue of A Shares and the listing on the SSE STAR Market.	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
5.	To consider and approve the proposal for accumulated profit distribution and the plan for undertaking unrecovered losses prior to the Issue of A Shares.	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
6.	To consider and approve the Company's three-year dividend distribution plan for Shareholders after Issue of A Shares and listing on the SSE STAR Market.	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
7.	To consider and approve the Company's share price stabilization plan and restraining measures within three years after the Issue of A Shares and listing on the SSE STAR Market.	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
8.	To consider and approve the undertakings and restraining measures relating to the Issue of A Shares and listing on the SSE STAR Market, and to authorize the Board to make appropriate undertakings for the purpose of the Issue of A Shares in accordance with the laws, regulations and regulatory documents of the PRC, the relevant regulations and policies of the securities regulatory departments, and combining the review for listing on the SSE STAR Market in practice and the actual situation of the Company.	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes
9.	To consider and approve the impact of dilution on immediate return by the Issue of A Shares and adoption of recovery measures.	99,857,306 (91.47%)	6,414,396 (5.88%)	2,896,824 (2.65%)	Yes

Notes:

- (1) Please refer to the notice of Class Meeting of H Shareholders and the Circular for details of these resolutions.
- (2) A special resolution is passed by more than two-thirds of the votes casted in favour of it.

POLL RESULTS OF THE CLASS MEETING FOR DOMESTIC SHAREHOLDERS AND UNLISTED FOREIGN SHAREHOLDERS

The poll results of the Class Meeting for Domestic Shareholders and Unlisted Foreign Shareholders were as follows:

	Special Resolutions⁽¹⁾	For	Against	Abstain	Passed by Shareholders⁽²⁾
1.	To consider and approve the fulfillment by the Company of the requirements for initial public offering of A Shares and listing on the SSE STAR Market.	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
2.	To consider and approve the proposed Issue of A Shares as follows:	(each and every item as a separate resolution)			
	(i) Class of new Shares to be issued;	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(ii) Nominal value of new Shares to be issued;	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(iii) Issue size;	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(iv) Method and schedule of issuance;	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(v) Target subscribers;	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(vi) Pricing methodology;	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(vii) Issuance expenses;	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(viii) Method of underwriting;	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(ix) Subscription by the Company's senior management and core employees;	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(x) Place of listing;	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
	(xi) Validity period of the resolutions.	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes

Special Resolutions⁽¹⁾		For	Against	Abstain	Passed by Shareholders⁽²⁾
3.	To consider and approve the investment projects to be funded by the proceeds raised from the Issue of A Shares and feasibility analysis.	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
4.	To consider and approve the authorization to the Board of Directors to fully handle matters in connection with the proposed Issue of A Shares and the listing on the SSE STAR Market.	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
5.	To consider and approve the proposal for accumulated profit distribution and the plan for undertaking unrecovered losses prior to the Issue of A Shares.	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
6.	To consider and approve the Company's three-year dividend distribution plan for Shareholders after Issue of A Shares and listing on the SSE STAR Market.	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
7.	To consider and approve the Company's share price stabilization plan and restraining measures within three years after the Issue of A Shares and listing on the SSE STAR Market.	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
8.	To consider and approve the undertakings and restraining measures relating to the Issue of A Shares and listing on the SSE STAR Market, and to authorize the Board to make appropriate undertakings for the purpose of the Issue of A Shares in accordance with the laws, regulations and regulatory documents of the PRC, the relevant regulations and policies of the securities regulatory departments, and combining the review for listing on the SSE STAR Market in practice and the actual situation of the Company.	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
9.	To consider and approve the impact of dilution on immediate return by the Issue of A Shares and adoption of recovery measures.	89,978,999 (100.00%)	0 (0.00%)	0 (0.00%)	Yes

Notes:

- (1) Please refer to the notice of Class Meeting for Domestic Shareholders and Unlisted Foreign Shareholders and the Circular for details of these resolutions.
- (2) A special resolution is passed by more than two-thirds of the votes casted in favour of it.

SCRUTINEERS

The H share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM. Two representatives of the Shareholders, a lawyer of Tian Yuan Law Firm, and a supervisor of the Company participated in the scrutiny of the poll results.

CHANGE OF MEMBERS OF THE BOARD AND ITS COMMITTEES

At the EGM, Mr. Shuifa GUI (“**Mr. Gui**”) and Mr. Jianzhong LIU (“**Mr. Liu**”) were appointed as independent non-executive Directors of the first session of the Board. The appointments of Mr. Gui and Mr. Liu shall come into effect immediately after the conclusion of the EGM and until the expiry of the term of the first session of the Board. For the biographical details of Mr. Gui and Mr. Liu, please refer to the announcement of the Company dated November 14, 2019. As at the date of this announcement, there has been no change in such information.

Dr. Pierre Armand MORGON ceased to be an independent non-executive Director of the Company, the chairman of the Remuneration and Assessment Committee and a member of the Nomination Committee upon conclusion of the EGM. Dr. Luis BARRETO ceased to be an independent non-executive Director of the Company, a member of the Remuneration and Assessment Committee and a member of the Nomination Committee upon conclusion of the EGM.

A meeting of the Board was held following the conclusion of the EGM and Class Meetings on November 29, 2019, on which (i) Mr. Gui was elected as the chairman of the Remuneration and Assessment Committee and a member of the Nomination Committee; and (ii) Mr. Liu was elected as a member of the Remuneration and Assessment Committee and the chairman of the Nomination Committee. Dr. Xuefeng YU ceased to be the chairman of the Nomination Committee and continues to be a member of the Nomination Committee upon conclusion of the meeting.

CHANGE OF MEMBERS OF THE BOARD OF SUPERVISORS

At the EGM, Ms. Jiangfeng LI (“**Ms. Li**”) was appointed as a supervisor of the first session of the board of supervisors of the Company (the “**Board of Supervisors**”). The appointment of Ms. Li shall come into effect immediately after the conclusion of the EGM and until the expiry of the term of the first session of the Board of Supervisors. For the biographical details of Ms. Li, please refer to the announcement of the Company dated November 14, 2019. As at the date of this announcement, there has been no change in such information.

Mr. Jixiang ZHU ceased to be a supervisor and the chairman of the Board of Supervisors upon conclusion of the EGM.

A meeting of the Board of Supervisors was held following the conclusion of the EGM and Class Meetings on November 29, 2019, on which Ms. Li was elected as the chairman of the Board of Supervisors.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, November 29, 2019

As at the date of this notice, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors